论文部分内容阅读
我院从1990年8月开始,采用汕头(鱼它)滨制药厂生产的盐(硫)酸阿霉素与进口阿霉素分组对比治疗64例中晚期肺癌患者,现报告于下。临床资料一、64例中晚期肺癌患者中,其中男性45例,女性19例,年龄23～75岁。临床诊断中心型肺癌35例,周围型肺癌29例,小细胞肺癌24例,鳞癌23例,腺癌17例。临床分期,Ⅲ期31例,Ⅳ期33例。均合并转移。疗效按全国统一规定,分完全缓解(CR),部分缓解(PR),稳定(S),进展(P)四级。疗效持续4周以上。毒性按世界卫生组织统一规定记分。0(无),Ⅰ(轻度)、Ⅱ(中度可耐受)。Ⅲ(重度不可耐受)。Ⅳ(严重并发症)。二、用药方法根据细胞病理学分类,两种化疗药物
From August 1990 in our hospital, 64 patients with advanced-stage lung cancer were treated with the doxorubicin (sulfate) acid produced by Shantou Pharmaceutical Co., Ltd. and imported doxorubicin, which is reported below. Clinical data I. 64 patients with advanced lung cancer, including 45 males and 19 females, aged 23 to 75 years old. There were 35 clinically diagnosed central lung cancers, 29 peripheral lung cancers, 24 small cell lung cancers, 23 squamous cell carcinomas, and 17 adenocarcinomas. Clinical stage was 31 cases in stage III and 33 cases in stage IV. All merger transfer. The curative effect was divided into four grades: complete remission (CR), partial remission (PR), stability (S), and progress (P) according to the national unified regulations. The curative effect lasted for more than 4 weeks. Toxicity is scored according to the uniform regulations of the World Health Organization. 0 (none), I (mild), II (medium tolerable). III (Severely intolerable). IV (severe complications). Second, the use of drugs according to the classification of cytopathology, two chemotherapeutic drugs